Elekta AB (OTCMKTS:EKTAY) Short Interest Update

Elekta AB (OTCMKTS:EKTAY) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 1,732 shares, an increase of 154.7% from the May 14th total of 680 shares. Based on an average trading volume of 3,159 shares, the short-interest ratio is currently 0.5 days. Currently, 0.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Zacks Research cut Elekta from a “hold” rating to a “strong sell” rating in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Elekta Trading Up 0.9%

Shares of OTCMKTS:EKTAY traded up $0.05 during midday trading on Friday, hitting $5.56. 1,890 shares of the stock were exchanged, compared to its average volume of 2,379. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -34.75 and a beta of 1.00. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.73 and a current ratio of 0.95. The business’s 50-day moving average price is $5.96 and its 200 day moving average price is $6.07. Elekta has a 12 month low of $4.35 and a 12 month high of $6.93.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings results on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. The company had revenue of $521.00 million for the quarter. Elekta had a positive return on equity of 10.67% and a negative net margin of 3.32%. Analysts predict that Elekta will post 0.43 earnings per share for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.